generate families of sigmoidal dose-response curves. Optimally efficient data analysis should involve simultaneous description of all curves, rather than fitting each one individually.
We have developed a general computerized method to describe the dose-response curves in terms of basal and maximal respn=s, E&h and curve shape or steepness. This facile method permits rigorous statistical analysis, provides a basis for pooling of information from separate experiments, and allows one to test which characteristics are shared by various curves. data analysis; curve fitting; hormone receptors; radioimmunoassay; neurotransmitters, DNA-RNA hybridization DOSE-RESPONSE CURVES from bioassays, radioreceptor assays, radioimmunoassays (RIA), and DNA-RNA hybridization are typically smooth, symmetrical, and sigmoidal (S-shaped) when the dose is portrayed on a logarithmic scale. Usually, these curves may be equally well described by the Gaussian cumulative distribution (probit analysis) or by a logistic model (15, 29) . The latter has advantages of mathematical simplicity and has been widely used for bioassay, radioimmunoassay, and related techniques (2, 4, 5, 7, 10, 12-14, 20, 27-29, 31, 33, 35-37) . The general form of the logistic function may be expressed as Y a-d --1 + (Xl@ + d where Y is the response; X, the arithmetic dose; a, the response when X = 0; d, the response for "infinite" dose;l c is the EDSo, i.e., the dose resulting in a response halfway between a and d; and b is a "slope factcr" that determines the steepness of the curve. This equation has been used as the basis for analysis of dose-response curves, individually.
When two or more dose-response curves have been constructed, the usual practice has been to characterize each one separately and then to compare the slopes and potencies, e.g., in terms of the ratios of the ED& However, this which is only approximate when applied to nonlinear models (11). Any constraint (parameter sharing) will increase the sum of squares of the residuals but will also decrease the effective number of parameters estimated.
If the gain in the number of degrees of freedom (number of data points minus number of estimated parameters) counterbalances the gain in the sum of squares of residuals, the F test will be small (around l), indicating the appropriateness of the constraints used. Randomness of the residuals (deviations of observed from predicted responses) is tested by evaluation of the number of "runs" of positive or negative residuals (1, 11). The data points are expected to be randomly distributed above and below the fitted curve if the model is appropriate.
Significant nonrandomness of the signs of the residuals indicates an inappropriate fit .
EXAMPLES
We shall illustrate the utility and versatility of this approach to data analysis, by means of four examples: 1) RIA estimation of relative potency, in this case of an iodinated antigen, to obtain a measure of specific activity; 2) comparison of agonists and antagonists in a neurotransmitter radio-receptor assay system; 3) in vitro bioassay of human chorionic gonadotrophin (hCG) and several of its deglycosylated derivatives; 4 example of simultaneous fitting of two sigmoidal curves is shown in Fig. 1, A and B. The potency estimate7 of labeled luteinizing hormone releasing hormone (lz51-labeled LHRH) relative to native LHRH was measured by RIA. The dose-response (bound/total ratio for labeled hormone or B/T) curve for the labeled hormone tested is compared to the standard RIA dose-response curve. In this application, the relative potency is identical with the specific activity in terms of radioactive counts per picogram of LHRH. Unconstrained curve fitting for the labeled ligand resulted in a physically impossible negative estimate of d. This curve did not extend sufficiently into the high-dose region because total radioactivity is limited in practice to approximately lo6 cpm per tube. Constraining both curves to share identical values of a and d (Fig. m) (as would be expected for a valid RIA system, assuming that nonspecific counts have been measured correctly) results in a more suitable fit. The specific activity of 12sI-labeled LHRH was estimated as 5,344 t 3,584 counts/pg when analyzing each curve separately, and as 3,251 t 220 counts/pg when using constraints. Thus, use of constraints has resulted in a dramatic tenfold reduction in the size of the confidence limits, when potency is calculated as the ratio of the ED&. The curves may also be constrained to share a common slope b with no significant decrease in the goodness of fit (Table 1) .
2) Radioreceptor assays for neurotransmitters. In radioligand assays for hormones and neurotransmitters (acetylcholin e, catecholamines, opiates, etc.), it is customary to construct dose-response curves for many analogues. Not uncommonly, these fall into groups of agonists and antagonists with similar properties, readily apparent by visual inspection of the dose-response curves. Here, we wish to characterize the ED,, or ID,,, ' The potency estimate of a test substance relative to a standard drug is the ratio of equipotent doses of the test and the reference substance.
There has been considerable debate on the applicability of the relative potency estimate method to nonparallel curves (8, 9, 16). In the case of nonparallelism, the horizontal distance between the two curves on a logarithmic scale and hence the potency estimate is variable.
For example, the potency estimate based on the ratio of doses producing half-maximal response (ED,,,) would differ from those based on ED,, or ED,,,. of each agent, its slope factor b and to quantitatively and objectively identify "families" of agents with identical b values (parallel curves). Figure 2 shows competitive binding curves for the labeled dopaminergic agonist dihydroergocryptine (r3H]DHEC) in the presence of increasing amounts of unlabeled antagonists (Fig. 26) and agonists (Fig. 28) . The curves for the antagonists ( Fig. 2A) can be constrained to be parallel (all b's equal) without any significant effect on the goodness of fit (Table 2) ; further, the common slope factor (b) can be set equal to a value of 1 without deleterious effect (Table 2) .
In contrast, each of the four curves for agonists (Fig.  28 ) has a slope factor (b) significantly lower than unity: 0.68 t-0.06, 0.45 _ + 0.04, 0.40 t 0.03, and 0.40 t 0.03. We infer that the curves for the agonists are not parallel because the additional constraint of parallelism results in a deterioration of goodness of fit, with a significant increase in the average scatter around the cu17res (increased F test value) and a significant nonrandomness of the residual signs (Table 3 ). This lack of parallelism for the agonists is mainly due to the first curve (apomorphine), which is steeper than the other three curves. 6.88* 3* 7 5 3* The number of observations was 10 for apomorphine (curve 1), dopamine (cunle Z), epinephrine (curve 31, and norepinephrine (curve 4). When all a's, b's, and d's are set equal, the F test is highly significant (P < 0.005), and some run tests (indicated by an asterisk) reach the level of significance (P = 0.05). Thus, we reject the hypothesis that all curves are parallel and share the same limits a and d.
These latter curves may be constrained TV be parallel (same b). Consideration of the nonparallelism of displacement curves for agonists and antagonists may lead to new insights into the mechanisms of interaction of these agents with their specific recentor and nermit classification of compounds.
3) Biossuy of partial agonists. In the bioassay of a family of agonists and partial agonists, the basal response level (a) may remain the same but the maximal response (d) will be smaller for the partial agonists. However, the curves may reveal the same "steepness" (same b). Appropriate evaluation of the potency estimate of the partial agonists can best be obtained by simultaneous constrained curve fitting. Figure 3 shows Leydig cell adenosine 3',5'-cyclic monophosphate accumulation in response to varying doses of hCG and two related partial agonists. The cuI7'es have been forced to share a common a and b. The additional constraint of a common c (ED,,) does not significantly alter the goodness of fit of the curves. Thus, these three curves would be nearly superimposable if their responses were normalized to 100% of their respective maximum. Whereas parameters b and c usually reflect intrinsic properties of the system, parameters a and d ofZen vary between experiments, depending on experimental conditions. Simultaneous curve fitting may be used as an elegant and efficient method for pooling information from several experiments while minimizing problems of between-experiment variability in some parameters. values were pooled for all curves within the same experiment while constraining the c values (C&) ta be equal for all curves for the same substance. The additional constraint of parallelism (common b) did not alter the goodness of fit. Forcing all the d values ti be equal in addition to the constraints for b and c resulted in significant degradation of the goodness of fit (Table 4) . In Fig. 4 Waud (37-39) has pioneered the use of computer analysis of families of dose-response curves. He has applied simultaneous curve fitting based on a threeparameter logistic equation for estimating dissociation constants of agonists and antagonists assayed by pharmacological "1Zull" methods. The computer pr&&ms that he developed are most appropriate for that specific purpose. The data analysis that we describe, being more general, may not be as efficient in such specialized cases because we do not specify any underlying relationship between the ED&s of the curves as for "null" methods applied to the case of competitive antagonists.
The four-parameter logistic equation often represents a significant improvement over the three-parameter version because the base-line level (or the background or the nonspecific level) is included among the parameters instead of being considered as a perfectly known constant (20, 29) . Provision for weighting may be essential when the range of observed responses is quite large, resulting in unavoidable nonuniformity of variance of the response metameter (30). Flexibility in the choice of the shared parameters and multiple statistical tests for goodness of fit constitute the major advances of the program described here. The use of constrained simultaneous curve fitting for testing the equality of parameters is preferable to testing the identity of parameters estimated from curves fitted individually.
The standard errors and confidence limits of parameter estimates in nonlinear regression are only approximate, and any conclusion regarding the equality of corresponding parameters is only approximate.
In contrast, simultaneous constrained curve fitting permits testing for equality of parameters by inspecting the consequences of forcing them to be equal.
Most investigators still use simple graphic methods and subjective visual curve fitting. Perhaps this has been justifiable: computerized curve fitting of one curve at a time may fail to converge on correct values or even converge at all. An experienced experimentalist will automatically employ constraints (forcing the curves to assume desired characteristics based on an underlying model or previous results). Now, the present computer program should retain the advantages of the subjective methods, but also provide objective estimates of the reliability of the parameters. In conclusion, we have described a simple computerized method for efficient data analysis of families of
